An upcoming disposable positive expiratory pressure (PEP) device for individuals with cystic fibrosis may lessen the occurrence of infections and subsequently, reduce antibiotic use and medical consultations, said researchers from the University of Limerick, Ireland.
Dengue patients aged 60 years and above or those with multiple comorbidities particularly diabetes, cardiovascular disease, and asthma, have an elevated risk for severe organ involvement, according to a Singapore study.
The standard first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with mutant EGFR is an EGFR tyrosine kinase inhibitor (TKI). However, most patients eventually progress despite high rates of response to first-line EGFR-TKI therapy. At the time of progression, more than half of the patients are found to have a point mutation (T790M) in the EGFR-encoding gene, which reduces the efficacy of EGFR-TKIs. Osimertinib (Tagrisso™, AstraZeneca), a third-generation EGFR-TKI, targets both EGFR and T790M resistance mutations and has shown promising efficacy in patients with EGFR T790M-positive NSCLC. At the 17th World Conference on Lung Cancer (WCLC) held recently in Vienna, Austria, Professor Vassiliki Papadimitrakopoulou of the University of Texas, MD Anderson Cancer Center, Houston, US, presented results of the AURA3 trial, which compared the efficacy of osimertinib with standard doublet chemotherapy in patients with EGFR T790M-positive advanced NSCLC. Professor Glenwood Goss of the University of Ottawa, Canada, discussed the efficacy of osimertinib in patients with central nervous system (CNS) metastases, while Professor Yi-Long Wu of the Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China, discussed the use of plasma vs tissue samples for detecting T790M resistance mutations to better target osimertinib therapy.